DiaMedica Therapeutics Q3 loss widens on higher R&D costs

Overview

• US biopharma firm's Q3 net loss widened yr/yr and missed analyst estimates

• Q3 loss per share met analyst expectations

Outlook

• Company expects ReMEDy2 interim analysis in acute ischemic stroke trial to complete in Q1 2027

• DiaMedica anticipates current cash will fund operations into Q4 2027

• Company expects R&D expenses to moderately increase as clinical trials progress

Result Drivers

• R&D EXPENSES - Higher R&D costs driven by expansion of clinical team, ongoing ReMEDy2 trial, start-up of Phase 2 preeclampsia trial, additional toxicity testing, and increased manufacturing activity

• G&A EXPENSES - Slight decrease in G&A expenses attributed to lower professional fees, partially offset by higher share-based compensation

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $14.00, about 44.9% above its November 11 closing price of $9.66

Reuters Recommended Reads

• Nov 12 - Assembly Biosciences Q3 net loss widens on increased R&D costs

• Nov 12 - Nektar Therapeutics Q3 loss widens on higher R&D and G&A expenses

• Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)